FGF21 Reporter Cell Line for Specific Serum Activity Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current assays for detecting FGF21 activity in human serum are hindered by interference from other growth factors using the same signal transduction pathway, necessitating a sensitive and specific detection method that minimizes such interference.
Innovation Solution
A mammalian cell line is developed with a heterologous polynucleotide construct containing a cis-acting regulatory sequence linked to a promoter, a chimeric transcription factor with Elk-1's trans-activation domain, and a cell surface receptor comprising FGFR1c and beta-Klotho, allowing for FGF21-specific signal transduction without interference from other growth factors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If a standard FGF21 detection assay is used, then FGF21 activity can be detected, but interference from other growth factors using the same signal transduction pathway occurs
Solution Approach 1:
The invention segments the detection system by introducing a chimeric transcription factor with a heterologous DNA-binding domain that specifically recognizes a heterologous cis-acting regulatory sequence. This segmentation ensures that only the chimeric transcription factor can activate the reporter gene, excluding endogenous transcription factors and other growth factors from interfering with the detection process
Solution Approach 2:
The chimeric transcription factor acts as an intermediary between the FGF21 signal and the reporter gene expression. It contains the trans-activation domain of Elk-1 fused to a heterologous DNA-binding domain, creating a specific mediator that links FGF21 receptor activation to reporter gene activation without allowing other growth factors to interfere
2Measurement precision
If sensitivity of FGF21 detection is increased, then detection limit is improved, but interference from normal human serum increases
Solution Approach 1:
The invention applies local quality by creating a localized specific interaction system within the cell. The chimeric transcription factor with heterologous DNA-binding domain creates a localized recognition system that specifically binds to the heterologous cis-acting regulatory sequence, ensuring high sensitivity while rejecting interference from serum components
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The cell line provides enhanced sensitivity and specificity in detecting FGF21 activity, achieving a lower EC50 and reduced interference from normal human serum, with improved detection sensitivity up to 1000-fold compared to existing methods.
Implementation Method 1
a chimeric transcription factor, wherein said chimeric transcription factor comprises the trans-activation domain of Elk-1 fused to a heterologous DNA binding domain capable of binding to said cis-acting regulatory sequence
Implementation Method 2
a cell surface bound heterodimeric receptor protein comprising a tyrosine kinase FGFR1c and a beta-Klotho protein
Implementation Method 3
a heterologous cis-acting regulatory sequence operably linked to a downstream promoter sequence, wherein said promoter is operably linked to an open reading frame encoding a first reporter protein
Data Source
AI summary
The present invention relates to a mammalian FGF21 responsive reporter cell line and method of using the same for detecting and optionally quantitating FGF21 activity in a test sample. The invention further relates to a method for detecting and optionally quantitating neutralizing antibodies against FGF21 present in a test sample using the reporter cell line of the present invention.